Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Study Information
Alliance Study ID: A091305
NCT Study ID (ClinicalTrials.gov): NCT02152137
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Thyroid & Neuroendocrine / Endocrine Cancers
Alliance Study Chair: Robert Smallridge, MD
Status: COMPLETED
Study Description
This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as efatutazone dihydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information